Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. FDA seeking market approval of Durezol (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.
the details can be read here.
No comments:
Post a Comment